

Hemospray Receives Additional Reimbursement

Hemospray Eligible for New Technology Add-on Payments (NTAP)

What is NTAP?

The Medicare New Technology Add-on Payment (NTAP) program used by the Centers for Medicare and Medicaid Services (CMS) was established to provide additional payment for new technologies/services in Medicare's hospital inpatient prospective payment system (IPPS). The intent of the additional payments is to provide a temporary payment mechanism for the use of new technologies in addition to the DRG payment amount the hospital would otherwise receive. The NTAPs are provided until CMS has an appropriate number of inpatient claims data for MS-DRG rate setting that reflected the added costs of the new technology.

To be eligible for NTAP, a technology must meet three criteria: 1) the technology must be considered new; 2) the technology must add significant cost to a hospital stay; 3) the technology must show substantial clinical improvement over current standards of care. In the fiscal year (FY) 2021 final rule published by CMS, it was determined that Hemospray meets all three criteria.

When does the payment go into effect?

Hospitals will be eligible to receive NTAP for Hemospray beginning October 1, 2020, for a period of up to three years.

ICD-10 Codes

One of the following ICD-10 codes **MUST** be reported on the claim for a hospital to be eligible for NTAP.

***XW0G886** (Introduction of mineral-based topical hemostatic agent into upper GI, via natural or artificial opening endoscopic, new technology group 6)*

***XW0H886** (Introduction of mineral-based topical hemostatic agent into lower GI, via natural or artificial opening endoscopic, new technology group 6)*

Payment Calculation

Each case where the total costs of the case are more than the MS-DRG payment, CMS will provide an add-on payment.

As stated in the FY2021 Hospital Inpatient Prospective Payment Final Rule from CMS, *"Under § 412.88(a)(2), we limit new technology add-on payments to the lesser of 65 percent of the average cost of the technology, or 65 percent of the costs in excess of the MS-DRG payment for the case. As a result, the maximum new technology add-on payment for a case involving the use of Hemospray is \$1,625.00 for FY 2021."*

Hemospray Eligible for Transitional Pass-Through Payments

What is Transitional Pass-Through Payment (TPT)?

The Medicare Transitional Pass-through (TPT) payment program used by the Centers for Medicare and Medicaid Services (CMS) was established to provide additional payment for new technologies/services in Medicare's Hospital Outpatient Prospective Payment System (OPPS). The intent of the additional payments is to provide a temporary payment mechanism for the use of new technologies in addition to the procedural payment amount the hospital would otherwise receive. The TPT payments are provided until CMS has an appropriate number of claims data for rate setting that reflected the added costs of the new technology.

How does CMS decide which technologies receive TPT?

To be eligible for TPT, a technology must meet three criteria: 1) the technology must be considered new; 2) the technology must add significant cost to a procedure; 3) the technology must show substantial clinical improvement over current standards of care. In the calendar year (CY) 2021 final rule published by CMS, it was determined that Hemospray meets all three criteria.

Who is eligible for TPT payments?

Hospitals paid under the Medicare Outpatient Prospective Payment System (OPPS) and ambulatory surgery centers will be eligible for TPT payments.

When does the payment go into effect?

Hospitals will be eligible to receive TPT payments beginning January 1, 2021, for a period of up to 3 years.

HCPCS Code


The following HCPCS code **MUST** be reported on the claim for a hospital to be eligible for TPT.

C1052 (Hemostatic agent, gastrointestinal, topical)

Payment Calculation

Medicare determines the TPT payment amount on a case-by-case basis for each hospital; it is not a standard amount. The TPT payment amount is calculated based on:

- ***Hospital's charges*** for the new technology, which includes a hospital's charge adjustment or markup to account for its operating and capital costs;
- ***Hospital's cost-to-charge ratio (CCR)***, which Medicare applies to the charges submitted to determine the estimated costs of items and services on the claim form; and
- The ***device related portion of the relevant APC*** payment amount.



Applicable CPT Codes

Ambulatory Payment Classification (APC)	CPT Codes	Medicare Payment Amount ¹ (National Avg.)
5302 (Level 2 Upper GI Procedures)	43227, 43255, 44366, 44378	\$1,741.59
5312 (Level 2 Lower GI Procedures)	44391, 45334, 45382	\$1,082.91

¹ CY 2023 Medicare Outpatient Prospective Payment System

Transitional Pass-Through Payment Calculation Example HCPCS Code C1052 (Hemostatic agent, gastrointestinal, topical)

Description	Amount
Hospital Purchase Price	\$2,450
Facility Markup	X 3
Hospital Charges to Medicare for Hemospray	\$7,350
Hospital Cost to Charge Ratio (CCR)	X 0.3
Medicare Calculated Cost for Hemospray	\$2,205
Minus Device Offset for APC 5302	- \$153
TPT Payment for Hemospray	\$2,052
Minus Hospital Purchase Price	- \$2,450
Hospital Cost to Add Hemospray	\$398

If you have further questions, please contact reimbursement@cookmedical.com



Disclaimer: The information provided herein reflects Cook's understanding of the procedure(s) and/or device(s) from sources that may include, but are not limited to, the CPT coding system; Medicare payment systems; commercially available coding guides; professional societies; and research conducted by independent coding and reimbursement consultants. This information should not be construed as authoritative. The entity billing Medicare and/or third party payers is solely responsible for the accuracy of the codes assigned to the services and items in the medical record. Cook does not, and should not, have access to medical records, and therefore cannot recommend codes for specific cases. When you are making coding decisions, we encourage you to seek input from the AMA, relevant medical societies, CMS, your local Medicare Administrative Contractor and other health plans to which you submit claims. Cook does not promote the off-label use of its devices.